Eco-friendly approach for determination of moxifloxacin in pharmaceutical preparations and biological fluids through fluorescence quenching of eosin Y.

An easy, verified spectrofluorimetric approach was established for the investigation of moxifloxacin in pure forms, pharmaceutical preparations, and biological fluids. The approach involves forming a binary complex of moxifloxacin and eosin Y in an acetate buffer with a pH of 3.6. The highest quenching of eosin Y with moxifloxacin occurs at 545 nm. Several factors, such as pH, buffer type and concentration, and eosin Y concentration, were carefully studied. The calibration graph showed a linear relationship between fluorescence intensity and moxifloxacin concentrations between 0.2 and 10 µg mL-1 with a correlation coefficient of 0.998. It was determined that the detection and quantification limits were 0.0322 µg mL-1 and 0.0976 µg mL-1, respectively. The impact of common excipients was investigated, but no interferences were discovered. Standard forms of moxifloxacin, pharmaceuticals, and biological samples have all been studied using the established methodology. The method, which successfully complied with ICH requirements, was used for the analysis of moxifloxacin in its pure form, pharmaceutical dosage forms, and biological samples. The percentage recoveries obtained were ranged from 99.50 to 102.50% for pharmaceutical preparations and from 100.50 to 102.50% for human blood plasma and urine. Proposed mechanisms for the reaction between moxifloxacin and eosin Y.

Adenoid cystic carcinoma of larynx.

This case report presents the clinical picture, diagnostic methodology, and surgical treatment of a 30 years old female patient, who presented with hoarseness of voice and difficulty in breathing. Direct laryngoscopy showed mass in right side of subglottic region, and biopsy-proven adenoid cystic carcinoma. Total laryngectomy was performed and patient was discharged three weeks postoperatively and doing well.